Morphic Holding Inc (MORF)
30.30
-0.52
(-1.69%)
USD |
NASDAQ |
May 31, 16:00
30.33
+0.03
(+0.10%)
After-Hours: 20:00
Morphic Research and Development Expense (Quarterly): 42.44M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 42.44M |
| December 31, 2023 | 39.85M |
| September 30, 2023 | 34.36M |
| June 30, 2023 | 35.72M |
| March 31, 2023 | 30.45M |
| December 31, 2022 | 24.70M |
| September 30, 2022 | 25.24M |
| June 30, 2022 | 25.65M |
| March 31, 2022 | 26.46M |
| December 31, 2021 | 23.66M |
| September 30, 2021 | 20.97M |
| June 30, 2021 | 24.55M |
| March 31, 2021 | 18.61M |
| Date | Value |
|---|---|
| December 31, 2020 | 18.75M |
| September 30, 2020 | 16.00M |
| June 30, 2020 | 19.92M |
| March 31, 2020 | 18.96M |
| December 31, 2019 | 16.82M |
| September 30, 2019 | 12.64M |
| June 30, 2019 | 13.91M |
| March 31, 2019 | 10.37M |
| December 31, 2018 | 7.287M |
| September 30, 2018 | 5.767M |
| June 30, 2018 | 5.293M |
| March 31, 2018 | 4.284M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
12.64M
Minimum
Sep 2019
42.44M
Maximum
Mar 2024
24.48M
Average
24.10M
Median
Research and Development Expense (Quarterly) Benchmarks
| Alnylam Pharmaceuticals Inc | 261.00M |
| Cytokinetics Inc | -- |
| Amicus Therapeutics Inc | 28.33M |
| Insmed Inc | 121.08M |
| Madrigal Pharmaceuticals Inc | 71.24M |